Skip to main content

Drug Interactions between daptomycin and Nikita

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DAPTOmycin pitavastatin

Applies to: daptomycin and Nikita (pitavastatin)

GENERALLY AVOID: There is the potential for additive musculoskeletal toxicity during coadministration of daptomycin and HMG-CoA reductase inhibitors. Cases of rhabdomyolysis have been reported with concomitant administration of simvastatin and daptomycin. This may be due to additive musculoskeletal toxicity as both HMG-CoA reductase inhibitors and daptomycin have caused myopathy and rhabdomyolysis when given alone.

MANAGEMENT: Use of HMG-CoA reductase inhibitors should be temporarily suspended in patients receiving daptomycin. All patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).

References

  1. (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
  2. (2003) "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc
  3. (2004) "Product Information. Vytorin (ezetimibe-simvastatin)." Merck & Co., Inc

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer